OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Drug class refractoriness, not number of prior lines of therapy, properly classify patients with relapsed and refractory multiple myeloma
Luciano J. Costa, Smith Giri, Susan Bal, et al.
British Journal of Haematology (2023) Vol. 200, Iss. 6, pp. 824-827
Open Access | Times Cited: 7
Luciano J. Costa, Smith Giri, Susan Bal, et al.
British Journal of Haematology (2023) Vol. 200, Iss. 6, pp. 824-827
Open Access | Times Cited: 7
Showing 7 citing articles:
Subsequent therapy and outcomes in patients with newly diagnosed multiple myeloma experiencing disease progression after quadruplet combinations
Gayathri Ravi, Susan Bal, Laura Joiner, et al.
British Journal of Haematology (2024) Vol. 204, Iss. 4, pp. 1300-1306
Open Access | Times Cited: 3
Gayathri Ravi, Susan Bal, Laura Joiner, et al.
British Journal of Haematology (2024) Vol. 204, Iss. 4, pp. 1300-1306
Open Access | Times Cited: 3
Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy
Charalampos Charalampous, Utkarsh Goel, Prashant Kapoor, et al.
Blood Advances (2023) Vol. 7, Iss. 16, pp. 4371-4380
Open Access | Times Cited: 8
Charalampos Charalampous, Utkarsh Goel, Prashant Kapoor, et al.
Blood Advances (2023) Vol. 7, Iss. 16, pp. 4371-4380
Open Access | Times Cited: 8
Real-world treatment patterns and clinical outcomes in patients with multiple myeloma previously treated with lenalidomide and an anti-CD38 monoclonal antibody
Karthik Ramasamy, Ravi Vij, David J. Kuter, et al.
Clinical Lymphoma Myeloma & Leukemia (2024)
Closed Access | Times Cited: 1
Karthik Ramasamy, Ravi Vij, David J. Kuter, et al.
Clinical Lymphoma Myeloma & Leukemia (2024)
Closed Access | Times Cited: 1
Maybe you can’t drive this CAR?
Benjamin A. Derman
Blood Advances (2024) Vol. 8, Iss. 4, pp. 1030-1031
Open Access
Benjamin A. Derman
Blood Advances (2024) Vol. 8, Iss. 4, pp. 1030-1031
Open Access
The landscape of clinical trials for heavily pretreated multiple myeloma: opportunity for more randomization?
Rohan Kapur, John McCarron, Sridevi Rajeeve, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2024), pp. 1-3
Closed Access
Rohan Kapur, John McCarron, Sridevi Rajeeve, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2024), pp. 1-3
Closed Access
Inclusion criteria of currently enrolling T‐cell engaging trials in multiple myeloma: Should we be focusing on lines of prior therapy?
Ghulam Rehman Mohyuddin, Rohan Kapur, Luciano J. Costa
British Journal of Haematology (2023) Vol. 202, Iss. 1
Open Access | Times Cited: 1
Ghulam Rehman Mohyuddin, Rohan Kapur, Luciano J. Costa
British Journal of Haematology (2023) Vol. 202, Iss. 1
Open Access | Times Cited: 1
Refractoriness to last line of therapy: how often is it mandated and reported? A systematic review of randomized myeloma trials
Poorva Bindal, Mimi Najjar, Kelly Koehn, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2023) Vol. 64, Iss. 7, pp. 1340-1343
Closed Access
Poorva Bindal, Mimi Najjar, Kelly Koehn, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2023) Vol. 64, Iss. 7, pp. 1340-1343
Closed Access
